Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study

Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacogenomics 2020-04, Vol.21 (5), p.325-335
Hauptverfasser:	Wolking, Stefan, Schulz, Herbert, Nies, Anne T, McCormack, Mark, Schaeffeler, Elke, Auce, Pauls, Avbersek, Andreja, Becker, Felicitas, Klein, Karl M, Krenn, Martin, Møller, Rikke S, Nikanorova, Marina, Weckhuysen, Sarah, Consortium, EpiPGx, Cavalleri, Gianpiero L, Delanty, Norman, Depondt, Chantal, Johnson, Michael R, Koeleman, Bobby Pc, Kunz, Wolfram S, Marson, Anthony G, Sander, Josemir W, Sills, Graeme J, Striano, Pasquale, Zara, Federico, Zimprich, Fritz, Weber, Yvonne G, Krause, Roland, Sisodiya, Sanjay, Schwab, Matthias, Sander, Thomas, Lerche, Holger
Format:	Artikel
Sprache:	eng
Schlagworte:	antiepileptic drugs genetic generalized epilepsy GWAS lamotrigine levetiracetam pharmacoresistance valproic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects with GGE – responsive or nonresponsive to lamotrigine, levetiracetam and valproic acid. Our GWAS of AED response revealed suggestive evidence for association at 29 genomic loci (p
ISSN:	1462-2416 1744-8042
DOI:	10.2217/pgs-2019-0179